title: Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?
abstract: Heart failure (HF) is the end result of a diverse set of causes such as genetic cardiomyopathies, coronary artery disease, and hypertension and represents the primary cause of hospitalization in Europe. This serious clinical disorder is mostly associated with pathological remodeling of the myocardium, pump failure, and sudden death. While the survival of HF patients can be prolonged with conventional pharmacological therapies, the prognosis remains poor. New therapeutic modalities are thus needed that will target the underlying causes and not only the symptoms of the disease. Under chronic cardiac stress, small noncoding RNAs, in particular microRNAs, act as critical regulators of cardiac tissue remodeling and represent a new class of therapeutic targets in patients suffering from HF. Here, we focus on the potential use of microRNA inhibitors as a new treatment paradigm for HF.
authors.affiliation: Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
authors.forename: Leonne E
authors.initials: LE
authors.lastname: Philippen
authors.affiliation: Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
authors.forename: Ellen
authors.initials: E
authors.lastname: Dirkx
authors.affiliation: Cristal Therapeutics BV, Maastricht, The Netherlands.
authors.forename: Jan B M
authors.initials: JB
authors.lastname: Wit
authors.affiliation: Center for Human Drug Research, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Koos
authors.initials: K
authors.lastname: Burggraaf
authors.affiliation: Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
authors.forename: Leon J
authors.initials: LJ
authors.lastname: de Windt
authors.affiliation: Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
authors.forename: Paula A
authors.initials: PA
authors.lastname: da Costa Martins
mesh_terms: D000818:Animals; D016375:Antisense Elements (Genetics) / Q000235:genetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D006333:Heart Failure / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000627:therapeutic use*; D009206:Myocardium / Q000473:pathology
chemical_list: D016375:Antisense Elements (Genetics); D035683:MicroRNAs